Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

BACKGROUND: 18F-FDG-PET/CT is the current standard technique to define minimal residual disease (MRD) outside the bone marrow (BM) in multiple myeloma (MM), recently standardised applying the Deauville scores (DS) to focal lesions (FS) and bone marrow uptake (BMS) and defining the complete metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamagni, Elena, Oliva, Stefania, Gay, Francesca, Capra, Andrea, Rota-Scalabrini, Delia, D'Agostino, Mattia, Belotti, Angelo, Galli, Monica, Racca, Manuela, Zambello, Renato, Gamberi, Barbara, Albano, Domenico, Bertamini, Luca, Versari, Annibale, Grasso, Mariella, Sgherza, Nicola, Priola, Claudia, Fioritoni, Francesca, Patriarca, Francesca, De Cicco, Gabriella, Villanova, Tania, Pascarella, Anna, Zucchetta, Pietro, Tacchetti, Paola, Fanti, Stefano, Mancuso, Katia, Barbato, Simona, Boccadoro, Mario, Musto, Pellegrino, Cavo, Michele, Nanni, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314158/
https://www.ncbi.nlm.nih.gov/pubmed/37396807
http://dx.doi.org/10.1016/j.eclinm.2023.102017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314158/
https://www.ncbi.nlm.nih.gov/pubmed/37396807
http://dx.doi.org/10.1016/j.eclinm.2023.102017

Ejemplares similares